A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors

[Image: see text] Rapid mutation of the influenza virus through genetic mixing raises the prospect of new strains that are both highly transmissible and highly lethal, and which have the ability to evade both immunization strategies (through mutation of hemagglutinin) and current therapies (through...

Descripción completa

Detalles Bibliográficos
Autores principales: Brant, Michael G., Wulff, Jeremy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516865/
https://www.ncbi.nlm.nih.gov/pubmed/23181823
http://dx.doi.org/10.1021/ol3027939
_version_ 1782252351901401088
author Brant, Michael G.
Wulff, Jeremy E.
author_facet Brant, Michael G.
Wulff, Jeremy E.
author_sort Brant, Michael G.
collection PubMed
description [Image: see text] Rapid mutation of the influenza virus through genetic mixing raises the prospect of new strains that are both highly transmissible and highly lethal, and which have the ability to evade both immunization strategies (through mutation of hemagglutinin) and current therapies (through mutation of neuraminidase). Inspired by a need for next-generation therapeutics, a synthetic strategy for a new class of rigid, bicyclic inhibitors of influenza neuraminidase is reported.
format Online
Article
Text
id pubmed-3516865
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-35168652012-12-07 A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors Brant, Michael G. Wulff, Jeremy E. Org Lett [Image: see text] Rapid mutation of the influenza virus through genetic mixing raises the prospect of new strains that are both highly transmissible and highly lethal, and which have the ability to evade both immunization strategies (through mutation of hemagglutinin) and current therapies (through mutation of neuraminidase). Inspired by a need for next-generation therapeutics, a synthetic strategy for a new class of rigid, bicyclic inhibitors of influenza neuraminidase is reported. American Chemical Society 2012-11-26 2012-12-07 /pmc/articles/PMC3516865/ /pubmed/23181823 http://dx.doi.org/10.1021/ol3027939 Text en Copyright © 2012 American Chemical Society http://pubs.acs.org This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org.
spellingShingle Brant, Michael G.
Wulff, Jeremy E.
A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors
title A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors
title_full A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors
title_fullStr A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors
title_full_unstemmed A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors
title_short A Rigid Bicyclic Platform for the Generation of Conformationally Locked Neuraminidase Inhibitors
title_sort rigid bicyclic platform for the generation of conformationally locked neuraminidase inhibitors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516865/
https://www.ncbi.nlm.nih.gov/pubmed/23181823
http://dx.doi.org/10.1021/ol3027939
work_keys_str_mv AT brantmichaelg arigidbicyclicplatformforthegenerationofconformationallylockedneuraminidaseinhibitors
AT wulffjeremye arigidbicyclicplatformforthegenerationofconformationallylockedneuraminidaseinhibitors
AT brantmichaelg rigidbicyclicplatformforthegenerationofconformationallylockedneuraminidaseinhibitors
AT wulffjeremye rigidbicyclicplatformforthegenerationofconformationallylockedneuraminidaseinhibitors

Ejemplares similares